News Four more drugs in keenly watched ALS trial miss the mark ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy.
News Prilenia eyes 2025 launch for Huntington’s drug pridopidine Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial.
News FDA names a new CDER director, choosing a biotech vet The FDA has rounded out its senior leadership by naming biopharma industry executive George Tidmarsh to the role of CDER director.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face